SELLAS Life Sciences (SLS) Retained Earnings (2010 - 2026)
SELLAS Life Sciences (SLS) reported Retained Earnings of -$283.4 million for Q1 2026, down 11.62% year-over-year from -$320.7 million in Q1 2025, and down 3.06% quarter-over-quarter from -$275.0 million in Q4 2025.
SELLAS Life Sciences (SLS) Retained Earnings (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Retained Earnings data on file, last reported at -$283.4 million in Q1 2026.
- Retained Earnings for Q1 2026 came in at -$283.4 million, down 11.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$283.4 million (down 11.62% YoY), and the FY2025 annual result was -$275.0 million, down 10.83% from the prior year.
- Retained Earnings retreated to -$283.4 million in Q1 2026 per SLS's latest filing, from -$275.0 million in the prior quarter.
- Over five years, Retained Earnings peaked at -$155.3 million in Q1 2022 and troughed at -$283.4 million in Q1 2026.
- A 5-year average of -$222.2 million and a median of -$226.8 million in 2024 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2025: Retained Earnings tumbled 31.12% in 2022, then fell 10.73% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$179.9 million in 2022, then fell by 20.76% to -$217.2 million in 2023, then declined by 14.21% to -$248.1 million in 2024, then slipped by 10.83% to -$275.0 million in 2025, then declined by 3.06% to -$283.4 million in 2026.
- Business Quant data shows SLS's Retained Earnings at -$283.4 million in Q1 2026, -$275.0 million in Q4 2025, and -$267.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | -283.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -283.40 Mn |
| Dec 31, 2025 | -274.99 Mn |
| Sep 30, 2025 | -267.30 Mn |
| Jun 30, 2025 | -260.54 Mn |
| Mar 31, 2025 | -253.90 Mn |
| Dec 31, 2024 | -248.13 Mn |
| Sep 30, 2024 | -241.40 Mn |
| Jun 30, 2024 | -234.28 Mn |
| Mar 31, 2024 | -226.80 Mn |
| Dec 31, 2023 | -217.24 Mn |
| Sep 30, 2023 | -209.10 Mn |
| Jun 30, 2023 | -199.84 Mn |
| Mar 31, 2023 | -191.00 Mn |
| Dec 31, 2022 | -179.90 Mn |
| Sep 30, 2022 | -170.80 Mn |
| Jun 30, 2022 | -163.80 Mn |
| Mar 31, 2022 | -155.35 Mn |
| Dec 31, 2021 | -138.60 Mn |
| Sep 30, 2021 | -132.00 Mn |
| Jun 30, 2021 | -124.92 Mn |